Results 61 to 70 of about 368,229 (351)

Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active

open access: yesArthritis Care &Research, EarlyView.
Objective This study aimed to identify in patients with systemic lupus erythematosus (SLE) with clinically active disease the attainment of frequency and determinants of Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) and the frequency and determinants of flare and damage accrual after target attainment.
Yanjie Hao   +39 more
wiley   +1 more source

Determinant Factors of Morbidity in Patients with Systemic Lupus Erythematosus

open access: yesActa Médica Portuguesa, 2017
Introduction: Severity in systemic lupus erythematosus may vary from mild to even fatal consequences. There are no biomarkers to predict the disease’s prognosis.
Margarida Jacinto   +3 more
doaj   +1 more source

Acute interstitial nephritis and drug-induced systemic lupus erythematosus due to chlorthalidone and amiodarone: A case report

open access: yesSAGE Open Medical Case Reports, 2020
Drug-induced lupus erythematosus has features distinct from primary systemic lupus erythematosus. It can occur with a wide variety of agents that result in the generation of anti-histone or other types of antibodies.
Umut Selamet   +5 more
doaj   +1 more source

Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus [PDF]

open access: yes, 2018
Background: Systematic lupus erythematosus (SLE) is characterized with various complications which can cause serious organ damage in the human body. Despite the significant improvements in disease management of SLE patients, the non-invasive diagnosis ...
Burkly, L.C.   +6 more
core   +1 more source

Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment

open access: yesArthritis Care &Research, EarlyView.
Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histologic features and treatment response.
Andrea Fava   +48 more
wiley   +1 more source

Serum interleukin-17 levels are associated with nephritis in childhood-onset systemic lupus erythematosus

open access: yesClinics, 2015
OBJECTIVES: To determine the serum interleukin-17 (IL-17) levels in childhood-onset systemic lupus erythematosus patients and to evaluate the association between IL-17 and clinical manifestations, disease activity, laboratory findings and treatment ...
Karina de Oliveira Peliçari   +7 more
doaj   +1 more source

Influence of 1 Alpha, 25-Dihydroxyvitamin D3 on T helper 17 cells and related cytokines in systemic lupus erythematosus [PDF]

open access: yes, 2015
Background: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease. Emerging data suggests that T helper 17 (Th17) cells play a pathogenic role in SLE and the increased number of these cells correlates with disease activity.
Abdollahi, N.   +7 more
core  

Role of brain perfusion SPECT with 99mTc HMPAO in the assessment of response to drug therapy in patients with autoimmune vasculitis: a prospective study [PDF]

open access: yes, 2015
BACKGROUND: The diagnosis of vasculitis in the brain remains a quite difficult achievement. To the best of our knowledge, there is no imaging method reported in literature which is capable of reaching to a diagnosis of vasculitis with very high ...
Anna Margherita Maffione, 2   +11 more
core   +1 more source

Human leucocyte antigens profiling in Malay female patients with systemic lupus erythematosus: are we the same or different? [PDF]

open access: gold, 2022
Malarvili Selvaraja   +7 more
openalex   +1 more source

Home - About - Disclaimer - Privacy